Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Longhua Technology Group Luoyang Co Ltd
SZSE:300263
|
CN |
Bioventus Inc
Total Assets
Bioventus Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Total Assets
$683.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Total Assets
$2.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
6%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Total Assets
$4.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Total Assets
$6.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
18%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Total Assets
$2.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
21%
|
CAGR 10-Years
25%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Total Assets
$2.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Total Assets?
Total Assets
683.6m
USD
Based on the financial report for Dec 31, 2025, Bioventus Inc's Total Assets amounts to 683.6m USD.
What is Bioventus Inc's Total Assets growth rate?
Total Assets CAGR 5Y
7%
Over the last year, the Total Assets growth was -6%. The average annual Total Assets growth rates for Bioventus Inc have been -21% over the past three years , 7% over the past five years .
